Micah T. Prochaska, MD, MSc | Image Credit: University of Chicago School of Medicine
A recent secondary analysis of data from the Myocardial Ischemia and Transfusion (MINT) trial has found no difference in quality of life (QOL) outcomes between liberal versus restrictive transfusion strategies in patients with myocardial infarction (MI) and anemia.1
Thanks to advances in acute MI therapies, the numbers of surviving patients with chronic coronary artery disease and impaired left ventricular function are rising. However, these patients are at a heightened risk for nonfatal and fatal cardiac events. Previous studies have indicated a generalized focus on secondary preventative efforts and attenuation of risk of consequences of the infarct. Equally important, though largely understudied, are health-related QOL changes…